logo-loader
viewe-Therapeutics plc

Drug developer e-Therapeutics streamlines its operation

“We are now focusing on our core strengths around our unique drug discovery platform and the discovery of novel preclinical drugs," said chairman Iain Ross.

genomics_58f71294e8023.jpg
The company is cutting the number of discovery projects to six from 12 in order to improve efficiency

Prelims from drug developer e-Therapeutics PLC (LON:ETX) charted a period of “fundamental change”, which included the appointment of a new chief executive and the focus on fewer projects.

The departure of Malcom Young last year saw the recruitment of Dr Ray Barlow from Amgen.

He will oversee the company’s ‘refocus’ towards drug discovery and the core in silico platform and away from clinical development.

CLICK to receive the the Proactive newsletter

As part of this drive, ETX is streamlining the number of discovery projects to six from 12 in order to improve efficiency.

The acquisition of a company called Searchbolt allowed ETX to secure ownership of its intellectual property.

"The business has changed fundamentally in the past 12 months,” said chairman Iain Ross.

“We are now focusing on our core strengths around our unique drug discovery platform and the discovery of novel preclinical drugs.

“The priority has been to ensure we have the right infrastructure, skills and capabilities in place to execute our business strategy. We approach the coming year with increasing optimism." 

The firm exited the year to January 31 with cash of £14mln. It posted an operating loss of £16.3mln, which included an impairment charge of £2.8mln, while its discovery spend was £7.6mln. It received R&D tax credits of £3.1mln.

Quick facts: e-Therapeutics plc

Price: 3.34 GBX

AIM:ETX
Market: AIM
Market Cap: £8.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Holding(s) in Company

on 11/08/2019

Holding(s) in Company

on 10/29/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Half-year Report

on 10/07/2019

Holding(s) in Company

on 09/17/2019

2 min read